209 related articles for article (PubMed ID: 31784538)
1. Myeloid lineage enhancers drive oncogene synergy in CEBPA/CSF3R mutant acute myeloid leukemia.
Braun TP; Okhovat M; Coblentz C; Carratt SA; Foley A; Schonrock Z; Curtiss BM; Nevonen K; Davis B; Garcia B; LaTocha D; Weeder BR; Grzadkowski MR; Estabrook JC; Manning HG; Watanabe-Smith K; Jeng S; Smith JL; Leonti AR; Ries RE; McWeeney S; Di Genua C; Drissen R; Nerlov C; Meshinchi S; Carbone L; Druker BJ; Maxson JE
Nat Commun; 2019 Nov; 10(1):5455. PubMed ID: 31784538
[TBL] [Abstract][Full Text] [Related]
2. Combined inhibition of JAK/STAT pathway and lysine-specific demethylase 1 as a therapeutic strategy in CSF3R/CEBPA mutant acute myeloid leukemia.
Braun TP; Coblentz C; Curtiss BM; Coleman DJ; Schonrock Z; Carratt SA; Callahan RL; Maniaci B; Druker BJ; Maxson JE
Proc Natl Acad Sci U S A; 2020 Jun; 117(24):13670-13679. PubMed ID: 32471953
[TBL] [Abstract][Full Text] [Related]
3. CSF3R Mutations are frequently associated with abnormalities of RUNX1, CBFB, CEBPA, and NPM1 genes in acute myeloid leukemia.
Zhang Y; Wang F; Chen X; Zhang Y; Wang M; Liu H; Cao P; Ma X; Wang T; Zhang J; Zhang X; Lu P; Liu H
Cancer; 2018 Aug; 124(16):3329-3338. PubMed ID: 29932212
[TBL] [Abstract][Full Text] [Related]
4. CSF3R mutations were associated with an unfavorable prognosis in patients with acute myeloid leukemia with CEBPA double mutations.
Su L; Gao S; Tan Y; Lin H; Liu X; Liu S; Yang Y; Sun J; Li W
Ann Hematol; 2019 Jul; 98(7):1641-1646. PubMed ID: 31041512
[TBL] [Abstract][Full Text] [Related]
5. CSF3R mutations have a high degree of overlap with CEBPA mutations in pediatric AML.
Maxson JE; Ries RE; Wang YC; Gerbing RB; Kolb EA; Thompson SL; Guidry Auvil JM; Marra MA; Ma Y; Zong Z; Mungall AJ; Moore R; Long W; Gesuwan P; Davidsen TM; Hermida LC; Hughes SB; Farrar JE; Radich JP; Smith MA; Gerhard DS; Gamis AS; Alonzo TA; Meshinchi S
Blood; 2016 Jun; 127(24):3094-8. PubMed ID: 27143256
[No Abstract] [Full Text] [Related]
6. Chemo-genomic interrogation of CEBPA mutated AML reveals recurrent CSF3R mutations and subgroup sensitivity to JAK inhibitors.
Lavallée VP; Krosl J; Lemieux S; Boucher G; Gendron P; Pabst C; Boivin I; Marinier A; Guidos CJ; Meloche S; Hébert J; Sauvageau G
Blood; 2016 Jun; 127(24):3054-61. PubMed ID: 27034432
[TBL] [Abstract][Full Text] [Related]
7. [Restratifying the prognosis of acute myeloid leukemia patients with CEBPA double mutations based on CSF3R mutations and measurable residual disease].
Su L; Tan YH; Lin H; Han W; Yang YP; Liu XL; Sun JN; Liu QJ; Gao SJ
Zhonghua Xue Ye Xue Za Zhi; 2022 Dec; 43(12):1021-1027. PubMed ID: 36709108
[No Abstract] [Full Text] [Related]
8. HoxA9 binds and represses the Cebpa +8 kb enhancer.
Peng L; Guo H; Ma P; Sun Y; Dennison L; Aplan PD; Hess JL; Friedman AD
PLoS One; 2019; 14(5):e0217604. PubMed ID: 31120998
[TBL] [Abstract][Full Text] [Related]
9. Differential Implications of CSF3R Mutations in t(8;21) and CEBPA Double Mutated Acute Myeloid Leukemia.
Wang B; Wen L; Wang Z; Chen S; Qiu H
Clin Lymphoma Myeloma Leuk; 2022 Jun; 22(6):393-404. PubMed ID: 34975010
[TBL] [Abstract][Full Text] [Related]
10. Laboratory evaluation and prognostication among adults and children with CEBPA-mutant acute myeloid leukemia.
Mendoza H; Podoltsev NA; Siddon AJ
Int J Lab Hematol; 2021 Jul; 43 Suppl 1():86-95. PubMed ID: 34288448
[TBL] [Abstract][Full Text] [Related]
11. Prevalence and impact of colony stimulating factor 3 receptor (CSF3R) mutations among Egyptian acute myeloid leukemia patients.
Aref S; El-Ghonemy M; Abouzeid T; El-Sabbagh A; El-Baiomy M
Leuk Res; 2014 Jun; 38(6):722-5. PubMed ID: 24746896
[TBL] [Abstract][Full Text] [Related]
12. [Roles of CEBPA mutation and expression abnormality in acute myeloid leukemia - review].
Wang LM; Xiao HW; Huang H
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Oct; 20(5):1256-60. PubMed ID: 23114160
[TBL] [Abstract][Full Text] [Related]
13. A Truncated Granulocyte Colony-stimulating Factor Receptor (G-CSFR) Inhibits Apoptosis Induced by Neutrophil Elastase G185R Mutant: IMPLICATION FOR UNDERSTANDING CSF3R GENE MUTATIONS IN SEVERE CONGENITAL NEUTROPENIA.
Qiu Y; Zhang Y; Hu N; Dong F
J Biol Chem; 2017 Feb; 292(8):3496-3505. PubMed ID: 28073911
[TBL] [Abstract][Full Text] [Related]
14. The clinical characteristics and prognosis of Chinese acute myeloid leukemia patients with CSF3R mutations.
Chen X; Xu J; Fang F; Xu Z; Tan Y; Chang J; Muyey DM; Wang H
Int J Lab Hematol; 2022 Apr; 44(2):364-370. PubMed ID: 34818692
[TBL] [Abstract][Full Text] [Related]
15. Complexity of CEBPA dysregulation in human acute myeloid leukemia.
Pabst T; Mueller BU
Clin Cancer Res; 2009 Sep; 15(17):5303-7. PubMed ID: 19706798
[TBL] [Abstract][Full Text] [Related]
16. Combined testing for CCAAT/enhancer-binding protein alpha (CEBPA) mutations and promoter methylation in acute myeloid leukemia demonstrates shared phenotypic features.
Szankasi P; Ho AK; Bahler DW; Efimova O; Kelley TW
Leuk Res; 2011 Feb; 35(2):200-7. PubMed ID: 20970189
[TBL] [Abstract][Full Text] [Related]
17. CEBPA gene mutations in Egyptian acute myeloid leukemia patients: impact on prognosis.
Awad MM; Aladle DA; Abousamra NK; Elghannam DM; Fawzy IM
Hematology; 2013 Mar; 18(2):61-8. PubMed ID: 22990006
[TBL] [Abstract][Full Text] [Related]
18. [Impact of
Li RQ; Wen XL; Zhang XL; Dong CX; Wang MF; Liu XX; Huang YJ; Tan YH; Chang JM; Zhang RJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Jun; 31(3):628-632. PubMed ID: 37356918
[TBL] [Abstract][Full Text] [Related]
19. Sporadic and Familial Acute Myeloid Leukemia with CEBPA Mutations.
Yuan J; He R; Alkhateeb HB
Curr Hematol Malig Rep; 2023 Oct; 18(5):121-129. PubMed ID: 37261703
[TBL] [Abstract][Full Text] [Related]
20. CCAAT/enhancer binding protein-alpha polymorphisms occur more frequently than mutations in acute myeloid leukemia and exist across all cytogenetic risk groups and leukemia subtypes.
Leecharendkeat A; Tocharoentanaphol C; Auewarakul CU
Int J Cancer; 2008 Nov; 123(10):2321-6. PubMed ID: 18729193
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
